Ganglioglioma

Diseases /

Back to Diseases List

Associated Genetic Biomarkers

ALK
ALK Fusion
ARAF
ARAF Mutation
BRAF
BRAF Fusion
BRAF Mutation
BRAF V600A
BRAF V600D
BRAF V600E
BRAF V600G
BRAF V600K
BRAF V600M
BRAF V600R
CRKL
CRKL Mutation
FGFR1
FGFR1 Mutation
FGFR2
FGFR2 Mutation

FGFR3
FGFR3 Mutation
H3F3A
H3F3A Codon 34 Missense
H3F3A Codon 35 Missense
H3F3A K27M
H3F3A K28M
HRAS
HRAS Mutation
IDH1

IDH1 Mutation
IDH2
IDH2 Mutation
KRAS
KRAS Mutation
MAP2K1
MAP2K1 Mutation
MAP2K2
MAP2K2 Mutation
MAP2K4

MAP2K4 Loss
MAP2K4 Mutation
MAP3K1
MAP3K1 Loss
MAP3K1 Mutation
MAPK1
MAPK1 Mutation
MYB
MYB Mutation
MYBL1

MYBL1 Mutation
NF1
NF1 Loss
NF1 Mutation
NF2
NF2 Loss
NF2 Mutation
NRAS
NRAS Mutation
NTRK1

NTRK1 Fusion
NTRK2
NTRK2 Fusion
NTRK3
NTRK3 Fusion
PTPN1
PTPN1 Mutation
RAF1
RAF1 Mutation
ROS1

ROS1 Fusion
SOS1
SOS1 Mutation
SRC
SRC Mutation

Overview

NCI Definition: A well differentiated, slow growing neuroepithelial neoplasm composed of neoplastic, mature ganglion cells and neoplastic glial cells. Some gangliogliomas show anaplastic features in their glial component and are considered to be WHO grade III. Rare cases of newly diagnosed gangliogliomas with grade IV (glioblastoma) changes in the glial component have also been reported. (Adapted from WHO) [1]

Gangliogliomas most frequently harbor alterations in BRAF, ZFHX3, NF1, KDR, and ARID1B [2].

Most Commonly Altered Genes in Ganglioglioma

BRAF Mutation, BRAF Exon 15 Mutation, BRAF V600E, BRAF Codon 600 Missense, and KDR Mutation are the most common alterations in ganglioglioma [2].

Top Alterations in Ganglioglioma

Biomarker-Directed Therapies

View Therapies for Ganglioglioma

Of the biomarker-directed therapies for ganglioglioma, 0 are FDA-approved in at least one setting and 4 have NCCN guidelines in at least one setting [3].

Cobimetinib + Vemurafenib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

BRAF V600E

Clinical Setting(s): Adjuvant (NCCN)

Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment.

Biomarker Criteria: Sample must match one or more of the following: BRAF V600E	Clinical Setting(s): Adjuvant (NCCN)
	Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment.

Dabrafenib + Trametinib +

Disease is predicted to be sensitive: -

Biomarker Criteria:

Sample must match one or more of the following:

BRAF V600E

Clinical Setting(s): Adjuvant (NCCN)

Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment.

Biomarker Criteria: Sample must match one or more of the following: BRAF V600E	Clinical Setting(s): Adjuvant (NCCN)
	Note: Per NCCN, may be useful in certain circumstances for adjuvant treatment.

Clinical Trials

View Clinical Trials for Ganglioglioma

There is 1 clinical trial for ganglioglioma, of which 1 is open and 0 are completed or closed. Of the trial that contains ganglioglioma as an inclusion criterion, 1 is phase 1/phase 2 (1 open).

ARAF, BRAF, and CRKL are the most frequent gene inclusion criteria for ganglioglioma clinical trials [3].

Trials Investigating Ganglioglioma by Gene and Recruiting Status

Mirdametinib is the most common intervention in ganglioglioma clinical trials.

Drugs Being Investigated in Ganglioglioma Trials by Recruiting Status

Significant Genes in Ganglioglioma

ARAF +

ARAF is altered in 1.19% of ganglioglioma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF +

BRAF is altered in 57.3% of ganglioglioma patients [2].

BRAF is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Cobimetinib, vemurafenib, dabrafenib, and trametinib have evidence of efficacy in patients with BRAF mutation in ganglioglioma [3].

CRKL +

CRKL is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 +

FGFR1 is altered in 4.49% of ganglioglioma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 +

FGFR2 is altered in 3.37% of ganglioglioma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 +

FGFR3 is altered in 1.12% of ganglioglioma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS +

HRAS is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

KRAS +

KRAS is altered in 2.25% of ganglioglioma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 +

MAP2K1 is altered in 4.6% of ganglioglioma patients [2].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 +

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 +

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 +

MAP3K1 is altered in 1.15% of ganglioglioma patients [2].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 +

MAPK1 is altered in 1.2% of ganglioglioma patients [2].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYB +

MYB is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MYB status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MYBL1 +

MYBL1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains MYBL1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 +

NF1 is altered in 6.9% of ganglioglioma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF2 +

NF2 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NF2 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NRAS +

NRAS is altered in 2.25% of ganglioglioma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTPN1 +

PTPN1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains PTPN1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 +

RAF1 is altered in 2.38% of ganglioglioma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SOS1 +

SOS1 is altered in 2.9% of ganglioglioma patients [2].

SOS1 is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains SOS1 status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC +

SRC is altered in 1.27% of ganglioglioma patients [2].

SRC is an inclusion eligibility criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

Disease Details

Synonyms

GANGLIOGLIOMA, UNDETERMINED

Parent(s)

Neuronal and Mixed Neuronal-Glial Tumors

OncoTree Name

Ganglioglioma

OncoTree Code

GNG

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Ganglioglioma

Back to Diseases List

Associated Genetic Biomarkers

Overview

Biomarker-Directed Therapies

Clinical Trials

Significant Genes in Ganglioglioma

Disease Details

References

About

Molecular Medicine

Content Types